Shi-He Liu
Overview
Explore the profile of Shi-He Liu including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
53
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghai S, Shrestha R, Hegazi A, Boualoy V, Liu S, Su K
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519208
Copper is crucial for many physiological processes across mammalian cells, including energy metabolism, neurotransmitter synthesis, and antioxidant defense mechanisms. However, excessive copper levels can lead to cellular toxicity and "cuproptosis",...
2.
Creeden J, Sevier J, Zhang J, Lapitsky Y, Brunicardi F, Jin G, et al.
J Control Release
. 2024 Mar;
368:413-429.
PMID: 38431093
Exosomes continue to attract interest as a promising nanocarrier drug delivery technology. They are naturally derived nanoscale extracellular vesicles with innate properties well suited to shuttle proteins, lipids, and nucleic...
3.
Zhang Y, Dong M, Xu P, Cai J, Liu S, Gao Y, et al.
Colloids Surf B Biointerfaces
. 2022 Aug;
218:112733.
PMID: 35981473
Effectively capturing, releasing, and reanalyzing circulating tumor cells (CTCs) are critical in cancer diagnosis and individualized treatment. Traditional immunomagnetic separation has disadvantages of low sensitivity and specificity, and is time-consuming...
4.
Creeden J, Alganem K, Imami A, Henkel N, Brunicardi F, Liu S, et al.
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33233470
Kinase drug discovery represents an active area of therapeutic research, with previous pharmaceutical success improving patient outcomes across a wide variety of human diseases. In pancreatic ductal adenocarcinoma (PDAC), innovative...
5.
Creeden J, Alganem K, Imami A, Brunicardi F, Liu S, Shukla R, et al.
Int J Mol Sci
. 2020 Nov;
21(22).
PMID: 33213062
Pancreatic cancer remains one of the most difficult malignancies to treat. Minimal improvements in patient outcomes and persistently abysmal patient survival rates underscore the great need for new treatment strategies....
6.
Chen C, Wu H, Kong D, Xu Y, Zhang Z, Chen F, et al.
Oncol Rep
. 2020 Oct;
44(6):2569-2580.
PMID: 33125137
Statins, a class of commonly prescribed cholesterol‑lowering medications, have been revealed to influence the risk of multiple types of cancer. However, the antitumor effects of statins on pancreatic cancer and...
7.
Liu S, Yu J, Creeden J, Sutton J, Markowiak S, Sanchez R, et al.
Cancer Lett
. 2020 Aug;
491:97-107.
PMID: 32829010
Patients with pancreatic adenocarcinoma (PDAC) have a 5-year survival rate of 8%, the lowest of any cancer in the United States. Traditional chemotherapeutic regimens, such as gemcitabine- and fluorouracil-based regimens,...
8.
Liu S, Hong Y, Markowiak S, Sanchez R, Creeden J, Nemunaitis J, et al.
Cancer Lett
. 2019 May;
457:10-19.
PMID: 31059751
Pancreatic ductal adenocarcinoma (PDAC) is a major cause of cancer mortality with a dismal overall survival rate and an urgent need for detection of minute tumors. Current diagnostic modalities have...
9.
Liu S, Yu J, Sanchez R, Liu X, Heidt D, Willey J, et al.
Cancer Lett
. 2018 Jan;
418:75-83.
PMID: 29309817
Our previous studies have shown that a rat insulin promoter II fragment (RIP) was used to effectively target pancreatic adenocarcinoma (PDAC) and insulinoma that over-express pancreatic and duodenal homeobox-1 (PDX-1)....
10.
Yu J, Liu S, Sanchez R, Nemunaitis J, Rozengurt E, Brunicardi F
Ann Transl Med
. 2016 Jul;
4(11):214.
PMID: 27386488
Pancreatic ductal adenocarcinoma (PDAC) is characterized by an extremely poor prognosis and a low median survival due to lack of the early and reliable detection and effective therapeutic options, despite...